High Point, North Carolina (June 8, 2018) —High Point Clinical Trials Center (HPCTC), North Carolina’s premier clinical research facility conducting clinical pharmacology testing of potential metabolic disease therapies, is offering free NASH screenings (nonalcoholic steatohepatitis) to those in the public at elevated risk for this largely underdiagnosed disease. This public service screening is offered to assist vulnerable individuals to determine their risk of developing NASH and other metabolic diseases as well as to share valuable information and resources around this public health concern.
As a disease, NASH remains predominantly unknown in the public as the Patients do not have overt symptomology and therefore it is underdiagnosed, even though approximately upwards of 12% of the nation’s adults suffer from or are at risk for NASH. By 2020 this “silent” disease is expected to become a public health crisis and the #1 reason for liver transplants in the U.S. There is currently no FDA approved medication for the treatment of NASH.
HPCTC joins national and international centers across the globe calling attention to this growing disease as we participate in the first International NASH Day, which will take place on June 12th, 2018 in more than 25 cities worldwide and through social media across the globe.
Certain health conditions—including obesity, metabolic syndrome, and type 2 diabetes—make individuals significantly more likely to develop NASH. NASH is closely associated with the triple epidemic of obesity, pre-diabetes, and diabetes, and can be defined as the liver manifestation of the metabolic syndrome. It is heavily influenced by lifestyle (e.g. chronic excessive calorie intake, sedentary activity) and is distinct from other fatty liver diseases caused by alcohol abuse or medication side effects.
NASH can lead to complications such as cirrhosis and liver cancer, meaning that Patients with significant disease progression have an increased chance of dying from liver-related causes. As there is no current medical intervention, Patients with NASH may progress to cirrhosis and ultimately liver failure, necessitating liver transplant.
NASH is also under-diagnosed because it is difficult to detect due to the lack of a simple, accurate and cost-effective diagnostic solution. HPCTC will be contributing to the education of the public on this topic by offering medical screenings to evaluate risk in interested individuals through June.
“Driving public education and the science of this looming epidemic at the community level is what differentiates HPCTC from other research facilities. We take an active lead in helping our neighbors, friends and family understand their medical risk for developing NASH and other metabolic diseases and how participating in a clinical trial supporting future therapies may benefit them,” states Dr. Lorraine M. Rusch, President of HPCTC .
Contact information is below:
To sign up for screening appointments, we invite all those interested to call 855-687-4257. A telephone screening will be conducted to determine eligibility. While June 12th is International NASH Day, screenings will be offered on days and times convenient to the caller’s schedule.
Note to media:
About High Point Clinical Trials Center (HPCTC)
HPCTC was “born from biotech” in 2008 as an internal clinical research unit for TransTech Pharma (now vTv Therapeutics), a drug discovery and development company. As the largest commercial clinical research unit in North Carolina, HPCTC conducts First-in-Human, clinical Proof-of-Concept, and traditional IND/NDA-enabling clinical pharmacology phase I/II trials for Contract Research Organizations, biotechnology and pharmaceutical companies worldwide.
In addition to early development studies, HPCTC conducts studies across a range of therapeutic areas including metabolic disorders, pulmonary disease and CNS in a pleasant and comfortable environment managed by caring and experienced staff. Participant safety, protocol adherence, regulatory compliance and effective communication are the Company’s top priorities.
Doug Copeland, Executive Vice President, Corporate Development
High Point Clinical Trials Center
+1 336 255 2353
Sponsors: Contact Our Team
Participants: Register for a Study